308 related articles for article (PubMed ID: 32207294)
1. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
[TBL] [Abstract][Full Text] [Related]
2. Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues.
Chen S; Yao H; Zhou Q; Tse MK; Gunawan YF; Zhu G
Inorg Chem; 2020 Aug; 59(16):11676-11687. PubMed ID: 32799457
[TBL] [Abstract][Full Text] [Related]
3. Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells.
Karmakar S; Kostrhunova H; Ctvrtlikova T; Novohradsky V; Gibson D; Brabec V
J Med Chem; 2020 Nov; 63(22):13861-13877. PubMed ID: 33175515
[TBL] [Abstract][Full Text] [Related]
4. Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells.
Almotairy ARZ; Montagner D; Morrison L; Devereux M; Howe O; Erxleben A
J Inorg Biochem; 2020 Sep; 210():111125. PubMed ID: 32521289
[TBL] [Abstract][Full Text] [Related]
5. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
6. Expanding the Arsenal of Pt
Yempala T; Babu T; Karmakar S; Nemirovski A; Ishan M; Gandin V; Gibson D
Angew Chem Int Ed Engl; 2019 Dec; 58(50):18218-18223. PubMed ID: 31599054
[TBL] [Abstract][Full Text] [Related]
7. Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups.
Zhou Q; Chen S; Xu Z; Liu G; Zhang S; Wang Z; Tse MK; Yiu SM; Zhu G
Angew Chem Int Ed Engl; 2023 Apr; 62(18):e202302156. PubMed ID: 36878864
[TBL] [Abstract][Full Text] [Related]
8. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
Gibson D
J Inorg Biochem; 2021 Apr; 217():111353. PubMed ID: 33477089
[TBL] [Abstract][Full Text] [Related]
9. Design and investigation of photoactivatable platinum(iv) prodrug complexes of cisplatin.
Lee VEY; Chin CF; Ang WH
Dalton Trans; 2019 Jun; 48(21):7388-7393. PubMed ID: 30957798
[TBL] [Abstract][Full Text] [Related]
10. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
11. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
Schmidt C; Babu T; Kostrhunova H; Timm A; Basu U; Ott I; Gandin V; Brabec V; Gibson D
J Med Chem; 2021 Aug; 64(15):11364-11378. PubMed ID: 34342437
[TBL] [Abstract][Full Text] [Related]
12. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
13. What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt E; Gibson D
J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
[TBL] [Abstract][Full Text] [Related]
14. Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity.
Aher S; Zhu J; Bhagat P; Borse L; Liu X
Top Curr Chem (Cham); 2024 Feb; 382(1):6. PubMed ID: 38400859
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin.
Bakalova AG; Buyukliev RT; Nikolova RP; Shivachev BL; Mihaylova RA; Konstantinov SM
Anticancer Agents Med Chem; 2019; 19(10):1243-1252. PubMed ID: 30767754
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato prodrugs.
Ravera M; Gabano E; Zanellato I; Fregonese F; Pelosi G; Platts JA; Osella D
Dalton Trans; 2016 Mar; 45(12):5300-9. PubMed ID: 26903367
[TBL] [Abstract][Full Text] [Related]
17. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations.
Song Y; Suntharalingam K; Yeung JS; Royzen M; Lippard SJ
Bioconjug Chem; 2013 Oct; 24(10):1733-40. PubMed ID: 23957697
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
[TBL] [Abstract][Full Text] [Related]
20. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]